Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2022 Illumina, Inc. All rights reserved. President & CEO, IlluminaFrancis deSouza40thAnnual J.P. Morgan Healthcare ConferenceJ.P. MORGAN HEALTHCARE CONFERENCE JANUARY 10, 2022
© 2022 Illumina, Inc. All rights reserved.
President & CEO, IlluminaFrancis deSouza40thAnnual
J.P. Morgan Healthcare ConferenceJ.P. MORGAN HEALTHCARE CONFERENCE JANUARY 10, 2022Cautionary Notes on Forward Looking Statements2 J.P. MORGAN HEALTHCARE CONFERENCE
This release may contain forward- looking statements that involve risks and uncertainties. Among the important
factors to which our business is subject that could cause actual results to differ materially from those in any forward-
looking statements are: ( i) the impact to our business and operating results of the COVID -19 pandemic; (ii)
challenges inherent in developing, manufacturing, and launching new products and services, (iii) our ability to further
develop and commercialize our instruments, consumables, and products, including Galleri , the cancer screening test
developed by GRAIL; (iv) the risks and costs associated with the integration of, and our ability to integrate, GRAIL’s
business successfully to achieve anticipated synergies, including the restrictions on integration while we are subject
to the European Commission’s order to keep GRAIL separate from us; (v) the risk that disruptions from the
consummation of our recent acquisition of GRAIL or any associated legal or regulatory proceedings or obligations
will harm our business, including current plans and operations; (vi) potential adverse reactions or changes to
business relationships resulting from the consummation of our recent acquisition of GRAIL; (vii) our ability to
successfully partner with other companies and organizations to develop new products, expand markets, and grow
our business, together with other factors detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10- K and 10- Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these
forward- looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on
the progress of the current quarter.Improve human health by unlocking the power of the genomeOUR MISSIONIllumina Sequencing Technology is Leading the
Rapidly Growing Genomics Diagnostic Tools MarketJ.P. MORGAN HEALTHCARE CONFERENCE
2021 revenue*Mid-Teens %
revenue growth target>400K
PublicationsWe enable clinicians and researchers to comprehensively
understand and leverage the genome4
For Research Use Only. Not for use in diagnostic procedures.Strong Finish to 2021 with 25% Revenue Growth in Q4J.P. MORGAN HEALTHCARE CONFERENCE
investor_presentation
PFSweb
Weatherford International Investor Presentation — April 2022
investor_presentationinvestor_presentation
18 Pages
Weatherford International plc
CONSOLIDATED RESULTS*
~$1.190BQ4 2021 REVENUE
Year -Over -Year GrowthRecord NovaSeq™ Shipments
Record NextSeq ™1000/2000 ShipmentsRecord Total Shipments
Preview truncated — download the full document for the complete content.
conference
31 Pages
investor_presentation
oOh!media Limited